Swiss Auto Components Stock News

Walliser Kantonalbank (SWX:WKBN) has reported its H1 2026 results with trailing 12 month revenue of CHF 276.4 million and net income of CHF 88.5 million, setting the stage against a backdrop where the net profit margin over the last year stood at 32% compared with 45% in the prior period. Over recent halves, the bank has seen revenue move from CHF 154.1 million in H2 2024 to CHF 135.7 million in H2 2025, alongside net income shifting from CHF 69.4 million to CHF 24.9 million. This leaves...

Swatch Group (SWX:UHR) has released its H1 2026 scorecard with trailing 12 month revenue of CHF6.4b and net income of CHF9m, set against a current share price of CHF186.35. The company has seen half year revenue move from CHF3.1b in H1 2025 to CHF3.2b in H2 2025, while net income shifted from CHF57m in H2 2024 to CHF3m and then CHF0m across the 2025 halves, leaving investors weighing weak recent profitability against analyst forecasts for 37.79% annual earnings growth. See our full analysis...

ALSO Holding (SWX:ALSN) has reported its H1 2026 numbers with revenue of about €7.1b and net income of €69.1m, while trailing twelve month revenue sits at roughly €14.7b with net income of €135.4m and EPS of €10.74. Over the past three reported half year periods, the company has seen revenue move from €5.9b in H1 2025 to €7.6b in H2 2025 and then to €7.1b in H1 2026, alongside net income shifting from €43.0m to €66.4m and then €69.1m, with EPS over the trailing twelve months at €10.74. For...

Novartis (SWX:NOVN) has posted fresh Q2 2026 numbers, with revenue at US$14.9 billion, basic EPS of US$1.71 and net income of US$3.3 billion, giving investors a clear read on how the business is currently earning its profits. Over recent quarters the company has seen revenue move between US$13.5 billion and US$14.9 billion, while basic EPS has ranged from US$1.26 to US$2.07. This provides a consistent earnings backdrop for assessing the latest release. With a trailing net profit margin of...

Chocoladefabriken Lindt & Sprüngli (SWX:LISN) has just posted its H1 2026 numbers, with revenue of CHF2.4 billion and basic EPS of CHF840.60, while trailing 12 month EPS sits at CHF3,204.72 on revenue of CHF5.9 billion. Over recent periods the company has reported revenue of CHF2,369.5 million in H1 2025, CHF3,580.9 million in H2 2025, and CHF2,365.7 million in H1 2026, with EPS of CHF812.70, CHF2,368.83, and CHF840.60 over the same intervals. With earnings reported as up 8.2% over the past...

Schindler Holding (SWX:SCHN) has put fresh numbers on the table for Q2 2026, reporting revenue of CHF 2.7b, net income of CHF 252m and basic EPS of CHF 2.50, set against trailing twelve month EPS of CHF 9.63 on revenue of CHF 10.8b. Over recent quarters, the company has seen revenue move between CHF 2.59b and CHF 2.79b with EPS ranging from CHF 2.26 to CHF 2.50. Over the past year, earnings grew about 4.1% and net margin improved to 9.5% from 8.9%. Investors are now weighing these steadier...

CPH Group (SWX:CPHN) has posted its H1 2026 results with trailing twelve month revenue of CHF 333.8 million and basic EPS of CHF 3.42, against a backdrop of prior-period swings in both the top and bottom line. Over recent half-year periods, revenue has moved from CHF 146.4 million in H2 2024 to CHF 175.96 million in H1 2025 and CHF 158.11 million in H2 2025, while basic EPS shifted from CHF 2.23 to CHF 2.85 and then CHF 1.04. The latest release therefore sits in the middle of a mixed trend...

Upcoming guidance call puts Partners Group Holding stock back in focus Partners Group Holding (SWX:PGHN) heads into its H1 2026 guidance and update call on 15 July after reporting record quarterly revenue of CHF 1.52b and net profit of CHF 682.5m. See our latest analysis for Partners Group Holding. Despite the record quarterly figures and the upcoming guidance call, Partners Group Holding’s share price is still under pressure, with a 90 day share price return down 27.17% and a 1 year total...

Earlier this month, Novartis received traditional FDA approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy at risk of disease progression, upgrading its earlier accelerated approval that was based on proteinuria reduction. The decision is grounded in two-year Phase III data showing Fabhalta’s first-in-class oral complement inhibition meaningfully slowed estimated glomerular filtration rate decline versus placebo, reinforcing...

What ABB’s latest results and guidance tell you ABB (SWX:ABBN) has drawn fresh attention after reporting second quarter 2026 results, updating its share buyback, and issuing guidance that outlines expected growth in comparable revenues and a positive book to bill ratio. For the quarter ended June 30, 2026, ABB reported revenue of US$9,475 million compared with US$8,295 million a year earlier. Net income was US$1,231 million, while basic earnings per share from continuing operations came in at...

Mikron Holding (SWX:MIKN) opened H1 2026 with revenue of CHF 180.5 million and basic EPS of CHF 0.83, while trailing twelve month revenue stood at CHF 370.6 million with basic EPS of CHF 1.68. This provides a clear snapshot of the company’s recent earnings power. Over the last three reported halves, revenue has ranged between CHF 180.5 million and CHF 191.9 million, with basic EPS moving between CHF 0.83 and CHF 1.10. This gives investors a tight read on how the top line and EPS have tracked...

Sandoz Group (SWX:SDZ) drew investor attention after announcing multiple leadership changes, including appointing Pascal Bouye to lead Generics Manufacturing & Supply and expanding M&A responsibilities for North America head Keren Haruvi. See our latest analysis for Sandoz Group. Sandoz Group’s latest executive reshuffle comes as the stock trades at CHF65.74, with the share price up 14.89% year to date and the 1 year total shareholder return at 45.41%. This suggests that momentum has eased in...

Europe’s growth story is increasingly shaped by companies tied to powerful themes like AI, automation, and digitalisation, and ASML is at the center of that conversation. Its recent Q2 update, with €9.3b in sales and 91 lithography systems sold, underlines how strongly AI-related demand is feeding into parts of the market. But a forward P/E near 50 also shows how quickly expectations can stretch. This article looks at three European Growth Stocks that are exposed to the same news backdrop as...

Swisscom (SWX:SCMN) is in focus after partnering with Sunrise to form a fraud risk consortium, using shared real time risk signals to help block cross carrier attacks and strengthen digital onboarding safeguards. See our latest analysis for Swisscom. Against this backdrop of tighter fraud controls, Swisscom’s share price is CHF634.0, with a 1 day share price return of 1.44% and a year to date share price return of 9.50%. The 1 year total shareholder return of 17.93% suggests momentum has been...

Regulators in the United States and European Union have widened access to several gene therapies, with the European Commission approving Novartis (SWX:NOVN) product onasemnogene abeparvovec for a broader group of patients with 5q spinal muscular atrophy. See our latest analysis for Novartis. Against this backdrop, Novartis shares are trading at CHF123.26, with a 30 day share price return of 2.97% and year to date share price return of 13.60%. The 1 year total shareholder return of 36.07%...

Alcon (SWX:ALC) is back in focus after announcing a non-exclusive collaboration with RxSight to co-develop adjustable presbyopia-correcting intraocular lenses. These lenses can be fine tuned after cataract surgery. See our latest analysis for Alcon. At a share price of CHF56.94, Alcon has seen short term momentum pick up, with a 1 month share price return of 8.42% and 7 day gain of 5.37%. However, the 1 year total shareholder return is down 17.89%, pointing to ongoing investor caution even as...

As geopolitical tensions and energy market volatility continue to influence the European markets, the pan-European STOXX Europe 600 Index recently experienced a decline of 1.79%. In this fluctuating environment, identifying stocks that are estimated to be trading below their intrinsic value can offer potential opportunities for investors seeking to navigate these uncertain times.

Why analyst sentiment around ams-OSRAM stock just shifted Recent analyst upgrades and higher earnings estimates have put ams-OSRAM (SWX:AMS) back on many investors’ radar, as the stock’s performance and sentiment move in tandem with these revised expectations. See our latest analysis for ams-OSRAM. ams-OSRAM’s CHF18.69 share price reflects a mixed recent pattern, with the stock down 3.16% on a 1 day share price return and 4.89% on a 30 day share price return, yet still showing a 61.40% 90 day...

In July 2026, Roche Holding received US FDA Priority Review for Gazyva/Gazyvaro in primary membranous nephropathy, a condition with no FDA approved therapies. Roche also launched the cobas HDV test, described as the first fully automated, high throughput diagnostic assay for Hepatitis D Virus. Both developments add to Roche Holding's immunology and virology portfolio and target areas with significant unmet medical need. For investors tracking Roche Holding (SWX:ROP), these July 2026...

Amidst geopolitical tensions and energy market volatility, the European stock market has faced challenges, with the pan-European STOXX Europe 600 Index recently experiencing a decline. Despite these uncertainties, dividend stocks remain an attractive option for investors seeking steady income streams in fluctuating markets. A strong dividend stock typically combines reliable payouts with a resilient business model that can withstand economic pressures and adapt to changing conditions.

In July 2026, Genpact announced it had partnered with Nestlé Business Solutions to build a new AI-enabled Global Capability Center in Hyderabad, India, while Nestlé also began tailoring recipes for GLP-1 users and launched its SparX Innovation Hub in Dubai to speed AI-driven product development in the MENA region. Together, these moves highlight how Nestlé is pairing process automation with rapid, data-led product innovation to respond more precisely to evolving health-focused consumer...

Julius Bär Gruppe (SWX:BAER) has drawn investor attention after appointing Peter Burrill as Chief Financial Officer and Executive Board member, replacing Evie Kostakis. His start is planned for August 2026, pending regulatory clearance. See our latest analysis for Julius Bär Gruppe. At a share price of CHF74.72, Julius Bär Gruppe has seen firm momentum recently, with a 30 day share price return of 15.49% and a 90 day share price return of 20.52%, while the 1 year total shareholder return of...

As geopolitical tensions and energy market volatility weigh on European markets, the STOXX Europe 600 Index recently saw a decline, reflecting investor concerns over potential inflationary pressures and monetary policy adjustments. Amidst this backdrop, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate uncertain times.

As geopolitical tensions and energy market volatility weigh on European equities, the pan-European STOXX Europe 600 Index has experienced a notable decline. Amidst these market dynamics, dividend stocks can offer investors a measure of stability and income potential, making them an attractive option in uncertain times.